公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
1998 | Characterization of a phage specific to hemorrhagic Escherichia coli O157:H7 and disclosure of variations in host outer membrane protein OmpC | SUNG-LIANG YU ; Ding H.-C.; Seah J.-N.; Wu K.-M.; Chang Y.-C.; Chang K.S.S.; Tam M.F.; Syu W.-J. | Journal of Biomedical Science | 14 | 0 | |
2000 | Characterization of the distal tail fiber locus and determination of the receptor for phage AR1, which specifically infects Escherichia coli O157:H7 | SUNG-LIANG YU ; Ko K.-L.; Chen C.-S.; Chang Y.-C.; Syu W.-J. | Journal of Bacteriology | 37 | 33 | |
2016 | ChemiRs: A web application for microRNAs and chemicals | Su E.C.-Y.; Chen Y.-S.; Tien Y.-C.; Liu J.; Ho B.-C.; SUNG-LIANG YU ; Singh S. | BMC Bioinformatics | 12 | 10 | |
2009 | Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma | Chao Y.-C.; SZU-HUA PAN ; Yang S.-C.; SUNG-LIANG YU ; Che T.-F.; CHUNG-WU LIN ; Tsai M.-S.; Chang G.-C.; Wu C.-H.; Wu Y.-Y.; Lee Y.-C.; Hong T.-M.; PAN-CHYR YANG | American Journal of Respiratory and Critical Care Medicine | 152 | 142 | |
2022 | Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia | Yu, Chih-Hsiang; SHIANN-TANG JOU ; Su, Ying-Hui; Coustan-Smith, Elane; Wu, Gang; Cheng, Chao-Neng; MENG-YAO LU ; Lin, Kai-Hsin; Wu, Kang-Hsi; Chen, Shu-Huey; Huang, Fang-Liang; HSIU-HAO CHANG ; Wang, Jinn-Li; Yen, Hsiu-Ju; MENG-JU LI ; SHU-WEI CHOU ; Ho, Wan-Ling; Liu, Yen-Lin; Chang, Chia-Ching; Lin, Ze-Shiang; Lin, Chien-Yu; Chen, Hsuan-Yu; Ni, Yu-Ling; Lin, Dong-Tsamn; SHU-WHA LIN ; Yang, Jun J; YEN-HSUAN NI ; Pui, Ching-Hon; SUNG-LIANG YU ; YUNG-LI YANG | Cancer | 0 | 0 | |
2022 | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Chin, Chun-Shih; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Cancer research and treatment | 8 | 6 | |
2018 | Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer | MONG-WEI LIN ; KANG-YI SU ; Su T.-J.; Chang C.-C.; Lin J.-W.; Lee Y.-H.; SUNG-LIANG YU ; JIN-SHING CHEN ; MIN-SHU HSIEH | Lung Cancer | 42 | 33 | |
2011 | Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations | Yuan S.; SUNG-LIANG YU ; Chen H.-Y.; Hsu Y.-C.; KANG-YI SU ; HUEI-WEN CHEN ; Chen C.-Y.; CHONG-JEN YU ; JIN-YUAN SHIH ; YIH-LEONG CHANG ; Cheng C.-L.; Hsu C.-P.; Hsia J.-Y.; Lin C.-Y.; Wu G.; Liu C.-H.; Wang C.-D.; Yang K.-C.; Chen Y.-W.; Lai Y.-L.; Hsu C.-C.; Lin T.-C.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen J.J.W.; Chang G.-C.; Li K.-C.; PAN-CHYR YANG | Journal of Clinical Oncology | 28 | 26 | |
2010 | Comparative Expression Profiles of mRNAs and microRNAs Among Human Mesenchymal Stem Cells Derived From Breast, Face, and Abdominal Adipose Tissues | Wang K.-H.; Kao A.-P.; Singh S.; SUNG-LIANG YU ; Kao L.-P.; Yun Tsai Z.; Lin S.-D.; Li S.S.-L. | Kaohsiung Journal of Medical Sciences | 14 | 12 | |
2012 | Comparative proteomic profiling of human lung adenocarcinoma cells (CL 1-0) expressing miR-372 | Lai J.-H.; She T.-F.; Juang Y.-M.; Tsay Y.-G.; Huang A.-H.; SUNG-LIANG YU ; Chen J.J.W.; Lai C.-C. | Electrophoresis | 18 | 16 | |
2020 | Copy Number Alterations of Depressed Colorectal Neoplasm Predict the Survival and Response to Oxaliplatin in Proximal Colon Cancer | LI-CHUN CHANG ; HAN-MO CHIU ; Ho, Bing-Ching; Chen, Min-Hsuan; Hsu, Yin-Chen; Chiu, Wei-Tzu; KANG-YI SU ; CHIA-TUNG SHUN ; JIN-TUNG LIANG ; SUNG-LIANG YU ; MING-SHIANG WU | Cancers | 5 | 5 | |
2022 | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 0 | 0 | |
1994 | Correlates and predictive models for blood pressure values in residents of two communities in Taiwan. | Pan W.H.; Chen Y.C.; SUNG-LIANG YU ; Sun J.A.; Chang Y.S.; Chen C.J. | Journal of the Formosan Medical Association = Taiwan yi zhi | 6 | 0 | |
2017 | Crosstalk between CLCb/Dyn1-Mediated Adaptive Clathrin-Mediated Endocytosis and Epidermal Growth Factor Receptor Signaling Increases Metastasis | PING-HUNG CHEN ; Bendris N.; Hsiao Y.-J.; Reis C.R.; Mettlen M.; Chen H.-Y.; SUNG-LIANG YU ; Schmid S.L. | Developmental Cell | 62 | 61 | |
2011 | Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: The versatile adjuvant for gefitinib therapy | Lee J.-Y.; Lee Y.-M.; Chang G.-C.; SUNG-LIANG YU ; Hsieh W.-Y.; Chen J.J.W.; HUEI-WEN CHEN ; PAN-CHYR YANG | PLoS ONE | 111 | 86 | |
2008 | Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1 | HUEI-WEN CHEN ; Lee J.-Y.; Huang J.-Y.; Wang C.-C.; Chen W.-J.; SHENG-FANG SU ; Huang C.-W.; CHAO-CHI HO ; Chen J.J.W.; Tsai M.-F.; SUNG-LIANG YU ; PAN-CHYR YANG | Cancer Research | 210 | 194 | |
2013 | Curcumin suppresses metastasis via Sp-1, FAK inhibition, and E-cadherin upregulation in colorectal cancer | Chen C.-C.; Sureshbabul M.; HUEI-WEN CHEN ; Lin Y.-S.; Lee J.-Y.; Hong Q.-S.; YA-CHIEN YANG ; SUNG-LIANG YU | Evidence-based Complementary and Alternative Medicine | 71 | 44 | |
2002 | Cyclosporine A regulate oxidative stress-induced apoptosis in cardiomyocytes: Mechanisms via ROS generation, iNOS and Hsp70 | HUEI-WEN CHEN ; Chien C.-T.; SUNG-LIANG YU ; Lee Y.-T.; WEN-JONE CHEN | British Journal of Pharmacology | 98 | 88 | |
2012 | Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus | HAO-CHIEH CHIU ; Lee S.-L.; Kapuriya N.; Wang D.; Chen Y.-R.; SUNG-LIANG YU ; Kulp S.K.; LEE-JENE TENG ; Chen C.-S. | Bioorganic and Medicinal Chemistry | 34 | 29 | |
2022 | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 7 | 7 | |